Sight Sciences Financial Results for Q1 2026 Show Growth

Published on May 8, 2026
MENLO PARK, Calif.—Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, has reported financial results for the first quarter ended March 31, 2026. In Q1, revenue was $19.7 million, an increase of 13 percent compared with the same period in the prior year. Interventional Glaucoma revenue was $18.3 million, an increase of 7 percent compared with the same period in 2025. The company attributed this improvement to an increase in both ordering accounts and average selling prices, slightly offset by lower utilization per account.
Continue reading on website
Other news

EyePoint Announces First Quarter 2026 Revenue Results

May 8, 2026
WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases, announced financial results for the first quarter ended March 31, 2026, and highlighted recent corporate developments. For the first quarter, total net revenue was $0.7 million, compared with $24.5 million for the same period in 2025. The decrease was primarily d

The Vision Council Testifies at USTR Hearings, Urges Exclusion of Eyewear and Optical Products From Possible Tariff Actions

May 8, 2026
ALEXANDRIA, Va.—The Vision Council announced this week that Omar Elkhatib, director of government relations, testified on behalf of the group and its members on May 5 at a public hearing held at the U.S. International Trade Commission in Washington, D.C., as part of a multi-day review of whether structural excess capacity in manufacturing abroad is harming U.S. production. During his testimony, he